US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

0.4575

+0.105830.08%

Post-market: 0.4400-0.0175-3.83%18:57 EDT

Volume:12.14M

Turnover:5.19M

Market Cap:25.92M

PE:-0.17

High:0.4760

Open:0.3636

Low:0.3636

Close:0.3517

52wk High:3.69

52wk Low:0.2500

Shares:56.66M

Float Shares:48.82M

Volume Ratio:10.00

T/O Rate:24.87%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6300

EPS(LYR):-2.7356

ROE:-2865.18%

ROA:-278.12%

PB:19.55

PE(LYR):-0.17

Loading ...

Overview Company News Filings

Medicus Pharma submits FDA rare pediatric disease designation request for SkinJect in Gorlin syndrome

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for Skinject® in Gorlin Syndrome

THOMSON REUTERS

Medicus Pharma Submits Drug Application for Genomics-Driven Teverelix Phase 2a Study

MT Newswires Live

Medicus Pharma submits IND to Abu Dhabi health regulator for Teverelix endometriosis trial

Medicus Pharma Initiates Groundbreaking Precision-E2 Phase 2a Study of Teverelix® in Endometriosis Utilizing the Emirati Genome Program

THOMSON REUTERS

Medicus Pharma Submits European Application for Prostate Cancer Drug Study

MT Newswires Live

Medicus Pharma submits substantial modification application through EU CTIS

Medicus Pharma submits EU CTIS application to amend Teverelix Phase 2b trial plan

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients With Key European Submission

THOMSON REUTERS

Medicus Pharma Shareholders Approve Auditor, Board and Consolidation

Medicus Pharma shareholders approve board authority for up to 1-for-50 share consolidation

Analysts Are Bullish on Top Healthcare Stocks: Health Catalyst (HCAT), Medicus Pharma Ltd (MDCX)

Medicus Pharma submits Protocol SKNJCT-005 to the FDA

Medicus Pharma submits FDA protocol for SkinJect registrational Gorlin syndrome study

Medicus Pharma Advances Skinject® Into Registrational Development for Gorlin Syndrome

THOMSON REUTERS

Medicus Pharma secures up to $22 million structured financing facility with institutional investor

Medicus Pharma Announces $22 Million Non-Dilutive Financing

THOMSON REUTERS

Medicus Pharma Secures Financing Amid Nasdaq Compliance Pressure

Medicus Pharma enters USD 22.86 million secured note deal with Streeterville Capital

Medicus Pharma reports Q1 EPS (31c), consensus (22c)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":0.4575,"timestamp":1781812800000,"preClose":0.3517,"halted":0,"volume":12142458,"hourTrading":{"tag":"盘后","latestPrice":0.44,"preClose":0.4575,"latestTime":"18:57 EDT","volume":658905,"amount":305066.75540250004,"timestamp":1781823423562,"change":-0.0175,"changeRate":-0.038251,"amplitude":0.185792},"delay":0,"changeRate":0.3008245663918112,"floatShares":48821600,"shares":56658200,"eps":-2.63,"marketStatus":"Post-Mkt","change":0.1058,"latestTime":"06-18 18:58:53 EDT","open":0.3636,"high":0.476,"low":0.3636,"amount":5191230.219885539,"amplitude":0.319591,"askPrice":0.4743,"askSize":100,"bidPrice":0.4232,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.63,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1781827200000},"marketStatusCode":4,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":0.3517,"preHourTrading":{"tag":"盘前","latestPrice":0.3634,"preClose":0.3517,"latestTime":"09:29 EDT","volume":20581,"amount":7434.301749599999,"timestamp":1781789399999,"change":0.0117,"changeRate":0.033267,"amplitude":0.067387},"postHourTrading":{"tag":"盘后","latestPrice":0.44,"preClose":0.4575,"latestTime":"18:57 EDT","volume":658905,"amount":305066.75540250004,"timestamp":1781823423562,"change":-0.0175,"changeRate":-0.038251,"amplitude":0.185792},"volumeRatio":9.996121},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":48821600,"roa":"-278.12%","roe":"-2865.18%","lyrEps":-2.735593,"volumeRatio":9.996121,"shares":56658200,"dividePrice":0,"high":0.476,"amplitude":0.319591,"preClose":0.3517,"low":0.3636,"week52Low":0.25,"pbRate":"19.55","week52High":3.69,"institutionHeld":0,"latestPrice":0.4575,"eps":-2.63,"divideRate":0,"volume":12142458,"delay":0,"ttmEps":-2.63,"open":0.3636,"prevYearClose":1.53,"prevWeekClose":0.3377,"prevMonthClose":0.379,"prevQuarterClose":0.459,"fiveDayClose":0.3328,"twentyDayClose":0.29,"sixtyDayClose":0.489},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-14","symbol":"MDCX","fiscalQuarterEnding":"2026/03","expectedEps":-0.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.31},{"market":"US","date":"2026-03-25","symbol":"MDCX","fiscalQuarterEnding":"2025/12","expectedEps":-0.32,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"post","actualEps":-0.82},{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"Post Market","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1776830400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-06-17","current":-0.149696,"percent":0.818627,"low":-3.23298,"twenty":-2.643859,"median":-0.962395,"eighty":-0.367901,"high":-0.235266,"avg":-1.278475,"sd":0.98315,"marketCap":18474579},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-13","current":-0.709738,"twenty":-2.853549,"median":-1.933403,"eighty":-0.974021,"marketCap":25373688},{"date":"2026-02-20","current":-0.786136,"twenty":-2.850483,"median":-1.381324,"eighty":-0.961937,"marketCap":28104981},{"date":"2026-02-27","current":-0.97195,"twenty":-2.849812,"median":-1.344224,"eighty":-0.949581,"marketCap":34747976},{"date":"2026-03-06","current":-0.484474,"twenty":-2.849812,"median":-1.300152,"eighty":-0.949581,"marketCap":17320333},{"date":"2026-03-13","current":-0.412761,"twenty":-2.835443,"median":-1.263181,"eighty":-0.891018,"marketCap":14756541},{"date":"2026-03-20","current":-0.412761,"twenty":-2.825864,"median":-1.220048,"eighty":-0.847322,"marketCap":14756541},{"date":"2026-03-27","current":-0.387698,"twenty":-2.82079,"median":-1.201563,"eighty":-0.836077,"marketCap":18330934},{"date":"2026-04-02","current":-0.349652,"twenty":-2.811211,"median":-1.179996,"eighty":-0.820403,"marketCap":16532085},{"date":"2026-04-10","current":-0.367967,"twenty":-2.792337,"median":-1.125793,"eighty":-0.786136,"marketCap":17398052},{"date":"2026-04-17","current":-0.250001,"twenty":-2.775573,"median":-1.109135,"eighty":-0.744685,"marketCap":11820441},{"date":"2026-04-24","current":-0.276475,"twenty":-2.764797,"median":-1.099378,"eighty":-0.508201,"marketCap":13072156},{"date":"2026-05-01","current":-0.235266,"twenty":-2.75402,"median":-1.088841,"eighty":-0.417566,"marketCap":11123732},{"date":"2026-05-08","current":-0.277717,"twenty":-2.74923,"median":-1.069002,"eighty":-0.412761,"marketCap":13130880},{"date":"2026-05-15","current":-0.393186,"twenty":-2.733353,"median":-1.041354,"eighty":-0.401798,"marketCap":18590424},{"date":"2026-05-22","current":-0.308017,"twenty":-2.714637,"median":-1.024243,"eighty":-0.38811,"marketCap":15777036},{"date":"2026-05-29","current":-0.354651,"twenty":-2.703729,"median":-1.018593,"eighty":-0.376126,"marketCap":18165658},{"date":"2026-06-05","current":-0.402361,"twenty":-2.691755,"median":-0.976444,"eighty":-0.374724,"marketCap":20609444},{"date":"2026-06-12","current":-0.35842,"twenty":-2.672597,"median":-0.968141,"eighty":-0.372398,"marketCap":18358733},{"date":"2026-06-17","current":-0.360682,"twenty":-2.643859,"median":-0.962395,"eighty":-0.367901,"marketCap":18474579}],"updateTime":1781795365240},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643322208","title":"Medicus Pharma submits FDA rare pediatric disease designation request for SkinJect in Gorlin syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2643322208","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643322208?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:30","pubTimestamp":1781523035,"startTime":"0","endTime":"0","summary":"Medicus Pharma submitted an FDA Rare Pediatric Disease Designation request for SkinJect to treat basal cell carcinoma in Gorlin syndrome patients.The filing follows an orphan drug designation application; the registrational study design remains under FDA review.Phase 2 data showed 64% clinical clearance, 55% complete response in the 200 ug arm.If granted and later approved, the designation could support eligibility for a rare pediatric disease priority review voucher.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL7TvKMn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","MDCX","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","NDAQ","SG9999014021.USD","BK4139","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643316208","title":"Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for Skinject® in Gorlin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2643316208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643316208?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:30","pubTimestamp":1781523000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA12V8J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642849952","title":"Medicus Pharma Submits Drug Application for Genomics-Driven Teverelix Phase 2a Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2642849952","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642849952?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:30","pubTimestamp":1781181027,"startTime":"0","endTime":"0","summary":"Medicus Pharma  said it submitted an Investigational New Drug application for the PRECISION-E2 Phase 2a study of Teverelix in women with symptomatic endometriosis, using the Emirati Genome Program to evaluate genomic predictors of treatment response, the company said Thursday.The study, submitted to the Department of Health Abu Dhabi as an Investigational New Drug application, is a randomized, placebo-controlled trial in about 84 patients in the UAE assessing safety, efficacy, pharmacodynamics and genomic response, the company said.Medicus said the trial will combine clinical, hormonal, pharmacokinetic and genomic data to assess treatment response variability while targeting controlled estradiol suppression and limiting side effects.The study could support further Phase 2b development of Teverelix and expansion into other estrogen-driven indications, while generating an integrated clinical and genomic precision-medicine dataset, it added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642454289","title":"Medicus Pharma submits IND to Abu Dhabi health regulator for Teverelix endometriosis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642454289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642454289?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:30","pubTimestamp":1781177458,"startTime":"0","endTime":"0","summary":"Medicus Pharma submitted an IND application to Abu Dhabi’s Department of Health for its PRECISION-E2 Phase 2a Teverelix study in endometriosis.The genomics-enabled trial plans to enroll about 84 women in the UAE, leveraging participants in the Emirati Genome Program.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL5rSc3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","MDCX","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","NDAQ","SG9999014021.USD","BK4139","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289118","title":"Medicus Pharma Initiates Groundbreaking Precision-E2 Phase 2a Study of Teverelix® in Endometriosis Utilizing the Emirati Genome Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289118?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:30","pubTimestamp":1781177400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA8BXT9F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641048470","title":"Medicus Pharma Submits European Application for Prostate Cancer Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2641048470","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641048470?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:55","pubTimestamp":1780923301,"startTime":"0","endTime":"0","summary":"Medicus Pharma  submitted a clinical modification application with the European Union to support an upcoming phase 2b trial of its advanced prostate cancer treatment Teverelix, the drugmaker said Monday.The phase 2b study aims to refine dosage options and analyze the safety, efficacy, and biological behavior of the therapy before starting registrational development, the company said.The drug candidate targets prostate cancer patients who have an elevated risk for cardiovascular issues and require androgen deprivation therapy, Medicus Pharma said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPV","MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641489731","title":"Medicus Pharma submits substantial modification application through EU CTIS","url":"https://stock-news.laohu8.com/highlight/detail?id=2641489731","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641489731?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:37","pubTimestamp":1780918661,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) announced the submission of a substantial modification application through the European Union Clinical Trials Information Sys...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-substantial-modification-application-through-eu-ctis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-substantial-modification-application-through-eu-ctis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPV","BK4156","MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641489134","title":"Medicus Pharma submits EU CTIS application to amend Teverelix Phase 2b trial plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2641489134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641489134?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:30","pubTimestamp":1780918240,"startTime":"0","endTime":"0","summary":"Medicus Pharma filed a substantial modification via the EU CTIS to support a planned Phase 2b Teverelix study in advanced prostate cancer.The application is under regulatory review; enrollment is targeted for later this year, subject to authorization.The trial is intended to support registrational planning focused on prostate cancer patients with elevated cardiovascular risk on androgen deprivation therapy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL5fsmPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4139","IE00BN0W2T93.GBP","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","BK4588","MDCX","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641941489","title":"Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients With Key European Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2641941489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641941489?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:30","pubTimestamp":1780918201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUAB0STJL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641826198","title":"Medicus Pharma Shareholders Approve Auditor, Board and Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2641826198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641826198?lang=en_us&edition=fundamental","pubTime":"2026-06-05 06:34","pubTimestamp":1780612461,"startTime":"0","endTime":"0","summary":"An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. On June 3, 2026, Medicus Pharma Ltd. held its 2026 Annual General and Special Meeti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-shareholders-approve-auditor-board-and-consolidation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-shareholders-approve-auditor-board-and-consolidation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641016783","title":"Medicus Pharma shareholders approve board authority for up to 1-for-50 share consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2641016783","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641016783?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:32","pubTimestamp":1780605129,"startTime":"0","endTime":"0","summary":"Medicus Pharma held its annual general and special meeting on June 3, 2026.Shareholders ratified KPMG LLP as independent registered public accounting firm for fiscal 2026; the board was authorized to set fees and terms.Shareholders approved a special resolution authorizing the board to consolidate common shares, at its discretion, up to a 50-for-1 ratio.The share consolidation was authorized but not executed; any consolidation remains subject to a separate board determination on timing and ratio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL2Srn84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640165061","title":"Analysts Are Bullish on Top Healthcare Stocks: Health Catalyst (HCAT), Medicus Pharma Ltd (MDCX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640165061","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640165061?lang=en_us&edition=fundamental","pubTime":"2026-06-04 23:20","pubTimestamp":1780586409,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Health Catalyst (HCAT) and Medicus Pharma Ltd (MDCX)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-health-catalyst-hcat-medicus-pharma-ltd-mdcx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-health-catalyst-hcat-medicus-pharma-ltd-mdcx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCAT","MDCX","BK4139","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640079989","title":"Medicus Pharma submits Protocol SKNJCT-005 to the FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2640079989","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640079989?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:37","pubTimestamp":1780493843,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) announced the submission of Protocol SKNJCT-005 to the FDA under the company’s existing investigational new drug, or IND, app...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-protocol-sknjct-005-to-the-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-protocol-sknjct-005-to-the-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IND","LABU","BK4585","MDCX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901615","title":"Medicus Pharma submits FDA protocol for SkinJect registrational Gorlin syndrome study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901615","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901615?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:01","pubTimestamp":1780488108,"startTime":"0","endTime":"0","summary":"Medicus submitted a Phase 2b registrational protocol for SkinJect in Gorlin syndrome under its existing FDA IND.Trial targets up to 50 patients; primary endpoint is complete visual clearance in at least 50% of selected lesions at Week 10.FDA orphan drug designation application filed in April; incentives could include waiver of NDA fees above USD 5 million, seven years of exclusivity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL713kk1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901569","title":"Medicus Pharma Advances Skinject® Into Registrational Development for Gorlin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901569?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUABNVXFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638981146","title":"Medicus Pharma secures up to $22 million structured financing facility with institutional investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2638981146","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638981146?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:03","pubTimestamp":1779969816,"startTime":"0","endTime":"0","summary":"Medicus Pharma entered a definitive structured financing facility of up to USD 22 million with an institutional investor.USD 12 million will be funded immediately; USD 10 million will be held in a collateralized deposit account for milestone-based releases.Facility includes a USD 12.86 million secured promissory note at 8.75% interest with a 6.5% original issue discount.Second tranche is a USD 10 million secured promissory note at 5% interest with no original issue discount.Pro forma cash is expected to rise to about USD 30 million; projected operating runway exceeds 24 months; notes mature in 18 months.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL39VCP7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014021.USD","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","NDAQ","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","BK4139","BK4588","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698623","title":"Medicus Pharma Announces $22 Million Non-Dilutive Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698623","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698623?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969607,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUAC3YKWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638634807","title":"Medicus Pharma Secures Financing Amid Nasdaq Compliance Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2638634807","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638634807?lang=en_us&edition=fundamental","pubTime":"2026-05-28 06:19","pubTimestamp":1779920379,"startTime":"0","endTime":"0","summary":"An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. On May 27, 2026, Medicus Pharma Ltd. closed a $22.86 million secured financin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-secures-financing-amid-nasdaq-compliance-pressure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-secures-financing-amid-nasdaq-compliance-pressure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638856639","title":"Medicus Pharma enters USD 22.86 million secured note deal with Streeterville Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2638856639","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638856639?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:45","pubTimestamp":1779914735,"startTime":"0","endTime":"0","summary":"Medicus Pharma closed a note purchase agreement with Streeterville Capital for two secured promissory notes totaling USD 22.86 million.Streeterville funded USD 12 million at closing; another USD 10 million was placed in a controlled deposit account at Lakeside Bank.Secured Promissory Note A-1 carries 8.75% interest, an USD 834,225 original issue discount; matures 18 months from issuance.Secured Promissory Note B carries 5% interest; no original issue discount; matures 18 months from issuance.About USD 2.5 million repaid and extinguished a YA II PN debenture; proceeds earmarked for clinical development, business development, general corporate uses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL1shSs3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635643724","title":"Medicus Pharma reports Q1 EPS (31c), consensus (22c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635643724","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635643724?lang=en_us&edition=fundamental","pubTime":"2026-05-15 06:18","pubTimestamp":1778797121,"startTime":"0","endTime":"0","summary":"“During the first quarter of 2026, Medicus continued to execute on its transformation into a diversified clinical-stage biotechnology company, high...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-reports-q1-eps-31c-consensus-22c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-reports-q1-eps-31c-consensus-22c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":109,"code":"91000000","status":"200"}]}}